Combining Cancer Immunotherapies

Targeted therapies act by blocking essential biochemical pathways or mutant proteins that are required for tumor cell growth and survival. These drugs can arrest tumor progression and induce striking regressions in molecularly defined subsets of patients. Indeed, the first small molecule targeted agent, the BCR-ABL kinase inhibitor imatinib, rapidly induced complete cytogenetic responses in 76% of chronic myelogenous leukemia patients. Further research into the underlying genetic pathways driving tumor proliferation uncovered additional oncoproteins that are critical for tumor maintenance, such as the epidermal growth factor receptor (EGFR), BRAF, KIT, HER (also known as neu and ERBB) and anaplastic lymphoma kinase (ALK). Similar to imatinib, small molecule inhibitors of these kinases have effectuated impressive tumor responses in selected patients, although regressions are commonly followed by the development of progressive disease due to the emergence of drug-resistant variants. Resistance usually involves secondary mutations within the targeted protein or compensatory changes within the targeted pathway that bypass the drug-mediated inhibition. Accordingly, targeted therapies may elicit dramatic tumor regressions, but persistence is generally short-lived, limiting the overall clinical benefit.

  • Targeted therapies
  • Rationale for immunotherapy
  • Combining radiotherapy
  • Standard therapies
  • Androgen manipulation
  • T-cell modulation

Related Conference of Combining Cancer Immunotherapies

June 29-July 01, 2017

8th European Immunology Conference

Madrid, Spain
July 03-04, 2017

9th Annual Meeting on Immunology and Immunologist

Kuala Lumpur, Malaysia
July 12-13, 2017

3rd World Conference on Parasitology & Pathogenesis

Chicago, Illinois, USA
August 07-08, 2017

Annual Summit on HIV/AIDS, STDs & STIs

Beijing, China
September 01-02, 2017

4th International Conference on Parasitology

Prague, Czech Republic
September 14-15, 2017

7th World Congress on Immunology

Amsterdam, Netherlands
September 21-22, 2017

International Conference on Parasitology and Infectious Diseases

San Antonio, Texas, USA
October 26-28 2017

Immunology-2017(CME & CPD accredited)

London, UK
November 01-03, 2017

Vaccines-2017 (CME & CPD Accredited)

Valencia, Spain
November 06-08, 2017

Infectious-diseases- 2017 (CME & CPD Accredited)

Valencia, Spain
November 2-3, 2017

9th World Congress and Expo on Immunology

Atlanta, Georgia, USA
November 02-03, 2017

9th World Congress on Immunity, Inflammation and Immunotherapies

Atlanta, Georgia, USA
November 06-07, 2017

2nd International Conference on Autoimmunity

Frankfurt, Germany
November 08-09, 2017

3rd Antibodies and Bio Therapeutics Congress

Las Vegas, Nevada, USA
November 13-14, 2017

5th International Conference on HIV/AIDS, STDs and STIs

Las Vegas, Nevada, USA
December 04-06, 2017

Oncology- 2017 (CME & CPD Accredited)

London, UK
Dec 14-15, 2017

World Immunology Congress

Dubai, UAE

Combining Cancer Immunotherapies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in